How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus–Associated Cryptococcal Meningitis to High-Income Settings?

Thomas S. Harrison, David S. Lawrence, Henry C. Mwandumba, David R. Boulware, Mina C. Hosseinipour, Olivier Lortholary, Graeme Meintjes, Mosepele Mosepele, Joseph N. Jarvis

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

The AmBisome Therapy Induction Optimization (AMBITION-cm) trial, conducted in eastern and southern Africa, showed that a single, high dose (10 mg/kg) of liposomal amphotericin B, given with an oral backbone of fluconazole and flucytosine, was noninferior to the World Health Organization (WHO)–recommended regimen of 7 days of amphotericin B deoxycholate plus flucytosine for treatment of human immunodeficiency virus (HIV)–associated cryptococcal meningitis and has been incorporated into WHO treatment guidelines. We believe that the trial also has important implications for the treatment of HIV-associated cryptococcal meningitis in high-income settings. We advance the arguments, supported by evidence where available, that the AMBITION-cm trial regimen is likely to be as fungicidal as the currently recommended 14-day liposomal amphotericin–based treatments, better tolerated with fewer adverse effects, and confer significant economic and practical benefits and, therefore, should be included as a treatment option in guidance for HIV-associated cryptococcal treatment in high-income settings.

Original languageEnglish (US)
Pages (from-to)944-949
Number of pages6
JournalClinical Infectious Diseases
Volume76
Issue number5
DOIs
StatePublished - Mar 1 2023

Bibliographical note

Publisher Copyright:
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Keywords

  • HIV
  • amphotericin B
  • cryptococcal meningitis
  • fluconazole
  • flucytosine

Fingerprint

Dive into the research topics of 'How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus–Associated Cryptococcal Meningitis to High-Income Settings?'. Together they form a unique fingerprint.

Cite this